Acute Coronary Syndrome: STEMI and NSTEMI Management Updates for 2026
Complete Revascularization in STEMI: COMPLETE and Beyond
The COMPLETE trial (4,041 STEMI patients with multivessel disease) demonstrated that staged complete revascularization of non-culprit lesions reduced the composite of cardiovascular death or MI by 26% (HR 0.74, 95% CI 0.60-0.91) compared to culprit-only PCI. The benefit was driven primarily by a reduction in MI (HR 0.68). The FIRE trial extended this evidence to patients over 75 years old, confirming benefit in the elderly with a 27% reduction in all-cause death, MI, or stroke at 1 year.
The MULTISTARS AMI trial addressed timing, demonstrating that immediate complete revascularization during the index procedure was non-inferior to staged complete revascularization, with a trend toward lower all-cause death or MI at 1 year (HR 0.77, 95% CI 0.54-1.11). This supports operator flexibility in managing non-culprit lesions during the initial catheterization when anatomy is favorable.
Antiplatelet Therapy: De-Escalation Strategies
The TWILIGHT trial established that ticagrelor monotherapy after 3 months of DAPT reduced BARC 2-5 bleeding by 44% (HR 0.56, p<0.001) without increasing ischemic events. The HOST-EXAM trial showed clopidogrel monotherapy was superior to aspirin monotherapy after 6-18 months of DAPT post-PCI, reducing a composite of cardiovascular events and bleeding by 27%. The STOPDAPT-3 trial introduced an aspirin-free strategy with prasugrel monotherapy from the time of PCI, though results were mixed on ischemic outcomes.
NSTEMI: Early Invasive vs Conservative Strategy
The ISCHEMIA trial established that an initial invasive strategy did not reduce death or MI compared to optimal medical therapy in stable ischemic heart disease. However, the ESC 2023 guidelines maintain that very-high-risk NSTEMI patients (hemodynamic instability, ongoing chest pain, life-threatening arrhythmias, acute heart failure) should undergo immediate angiography within 2 hours. High-risk patients (GRACE score >140, troponin rise/fall, dynamic ST changes) should undergo early angiography within 24 hours.
Sponsored
Adjunctive Pharmacotherapy Updates
High-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 40 mg) should be initiated in all ACS patients regardless of baseline LDL. If LDL remains above 55 mg/dL at 4-6 weeks despite maximally tolerated statin, ezetimibe 10 mg should be added. PCSK9 inhibitors (evolocumab or alirocumab) are recommended if LDL remains above target. The CLEAR Outcomes trial validated bempedoic acid as an alternative for statin-intolerant patients, with a 13% reduction in MACE (HR 0.87, 95% CI 0.79-0.96).
Cardiac Arrest and STEMI: TOMAHAWK Implications
The TOMAHAWK trial challenged the routine immediate angiography approach in out-of-hospital cardiac arrest patients without ST-elevation, finding no benefit and a signal toward harm (30-day mortality 54% immediate vs 46% delayed, HR 1.28, 95% CI 1.00-1.63). Current consensus favors immediate angiography only when there is a high suspicion of acute coronary occlusion (persistent ST-elevation, hemodynamic instability suggestive of ischemia), while stable post-arrest patients without ST-elevation should be stabilized and undergo delayed angiography.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.